Heinz-A. Horst

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 913 citations · Full text

Medicine, Hematology, Oncology +16

<i>IDH1</i>and<i>IDH2</i>Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With<i>NPM1</i>Mutation Without<i>FLT3</i>Internal Tandem Duplication

Peter Paschka, Richard F. Schlenk, Verena I. Gaidzik et al. · Journal of Clinical Oncology · 2010 · 791 citations

Life Sciences, Genetics, Hematology +16

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger et al. · Blood · 2015 · 161 citations · Full text

Medicine, Immunology, Oncology +16

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial

Peter Paschka, Richard F. Schlenk, Daniela Weber et al. · Leukemia · 2018 · 107 citations

Medicine, Hematology, Oncology +10

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients

Michela Tassara, Konstanze Döhner, Peter Brossart et al. · Blood · 2014 · 79 citations · Full text

Medicine, Oncology, Pharmacology +12